Skip to main content

Advertisement

SpringerLink
Log in

Association between NAD(P)H:quinone oxidoreductase 1 rs1800566 polymorphism and risk of bladder cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

NAD(P)H:quinone oxidoreductase 1 (NQO1) rs1800566 (Pro187Ser) is a functional polymorphism which leads to a proline-to-serine amino acid substitution at codon 187 in the NQO1 protein and enzyme activity changes. NQO1 rs1800566 polymorphism was implicated to be associated with a risk of bladder cancer, but published studies showed inconclusive results. We performed a meta-analysis of nine publications with a total of 2,661 cases and 2,738 controls on the association between NQO1 rs1800566 polymorphism and risk of bladder cancer. Data were extracted from those included studies, and the pooled odds ratio (OR) with the corresponding 95 % confidence interval (95 % CI) was calculated to assess the association. We found that there was no association between NQO1 rs1800566 polymorphism and risk of bladder cancer under all four genetic models (Ser vs. Pro, OR = 1.06, 95 % CI = 0.97–1.16, P = 0.21, I 2 = 31 %; SerSer vs. ProPro, OR = 1.12, 95 % CI = 0.89–1.42, P = 0.33, I 2 = 44 %; SerSer/ProSer vs. ProPro, OR = 1.08, 95 % CI = 0.96–1.21, P = 0.20, I 2 = 27 %; SerSer vs. ProPro/ProSer, OR = 1.06, 95 % CI = 0.85–1.32, P = 0.59, I 2 = 36 %). Meta-analysis of those eight studies from Europeans also showed that there was no association between NQO1 rs1800566 polymorphism and risk of bladder cancer under all four genetic models (Ser vs. Pro, OR = 1.02, 95 % CI = 0.93–1.13, P = 0.66, I 2 = 20 %; SerSer vs. ProPro, OR = 0.99, 95 % CI = 0.75–1.30, P = 0.93, I 2 = 38 %; SerSer/ProSer vs. ProPro, OR = 1.04, 95 % CI = 0.92–1.17, P = 0.55, I 2 = 6 %; SerSer vs. ProPro/ProSer, OR = 0.98, 95 % CI = 0.75–1.28, P = 0.87, I 2 = 39 %). This meta-analysis suggests that the NQO1 rs1800566 polymorphism is not associated with a risk of bladder cancer. Further studies with larger samples are needed, especially for studies in Asians and Africans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Oosterlinck W. Chemotherapy: electromotive mitomycin in superficial bladder cancer. Nat Rev Clin Oncol. 2011;8:633–4.

    Article  PubMed  CAS  Google Scholar 

  2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–49.

    Article  PubMed  CAS  Google Scholar 

  3. Schmitz-Drager BJ. Identifying risk factors in patients with non-muscle-invasive bladder cancer: clinical implications. Eur Urol. 2011;60:721–3.

    Article  PubMed  Google Scholar 

  4. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol. 2009;4:251–85.

    Article  PubMed  CAS  Google Scholar 

  5. Kawata N, Tsuchiya N, Horikawa Y, Inoue T, Tsuruta H, Maita S, et al. Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer. 2011;129:1872–80.

    Article  PubMed  CAS  Google Scholar 

  6. Koay EJ, Teh BS, Paulino AC, Butler EB. A surveillance, epidemiology, and end results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends. Cancer. 2011;117:5325–33.

    Article  PubMed  Google Scholar 

  7. Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys. 2010;501:116–23.

    Article  PubMed  CAS  Google Scholar 

  8. Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol. 2012;83:1033–40.

    Article  PubMed  CAS  Google Scholar 

  9. Nioi P, Hayes JD. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res. 2004;555:149–71.

    Article  PubMed  CAS  Google Scholar 

  10. Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA. NQO1 polymorphisms and de novo childhood leukemia: a huge review and meta-analysis. Am J Epidemiol. 2008;168:1221–32.

    Article  PubMed  Google Scholar 

  11. Schulz WA, Krummeck A, Rosinger I, Eickelmann P, Neuhaus C, Ebert T, et al. Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 1997;7:235–9.

    Article  PubMed  CAS  Google Scholar 

  12. Park SJ, Zhao H, Spitz MR, Grossman HB, Wu X. An association between NQO1 genetic polymorphism and risk of bladder cancer. Mutat Res. 2003;536:131–7.

    Article  PubMed  CAS  Google Scholar 

  13. Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, et al. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis. 2004;25:973–8.

    Article  PubMed  CAS  Google Scholar 

  14. Moore LE, Wiencke JK, Bates MN, Zheng S, Rey OA, Smith AH. Investigation of genetic polymorphisms and smoking in a bladder cancer case–control study in Argentina. Cancer Lett. 2004;211:199–207.

    Article  PubMed  CAS  Google Scholar 

  15. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.

    Article  PubMed  CAS  Google Scholar 

  16. Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263–71.

    Article  PubMed  CAS  Google Scholar 

  17. Terry PD, Umbach DM, Taylor JA. No association between SOD2 or NQO1 genotypes and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:753–4.

    Article  PubMed  CAS  Google Scholar 

  18. Figueroa JD, Malats N, Garcia-Closas M, Real FX, Silverman D, Kogevinas M, et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis. 2008;29:1955–62.

    Article  PubMed  CAS  Google Scholar 

  19. Wang YH, Lee YH, Tseng PT, Shen CH, Chiou HY. Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol. 2008;134:203–9.

    Article  PubMed  CAS  Google Scholar 

  20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

    PubMed  CAS  Google Scholar 

  21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  PubMed  CAS  Google Scholar 

  22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  PubMed  Google Scholar 

  23. Choi JY, Lee KM, Cho SH, Kim SW, Choi HY, Lee SY, et al. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics. 2003;13:349–55.

    Article  PubMed  CAS  Google Scholar 

  24. Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 2011;71:7376–86.

    Article  PubMed  CAS  Google Scholar 

  25. Wang Z, Xue L, Chong T, Li H, Chen H. Quantitative assessment of the association between glutathione S-transferase P1 Ile105Val polymorphism and bladder cancer risk. Tumour Biol. 2013;34(3):1651–7.

    Article  PubMed  CAS  Google Scholar 

  26. Zhang Y, Wang X, Zhang W, Gong S. An association between XPC Lys939gln polymorphism and the risk of bladder cancer: a meta-analysis. Tumour Biol. 2013;34:973–82.

    Article  PubMed  CAS  Google Scholar 

  27. Ding R, Lin S, Chen D. Association of NQO1 rs1800566 polymorphism and the risk of colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2012;27:885–92.

    Article  PubMed  Google Scholar 

  28. Yanling H, Yuhong Z, Wenwu H, Lei X, Mingwu C. NQO1 C609T polymorphism and esophageal cancer risk: a huge review and meta-analysis. BMC Med Genet. 2013;14:31.

    Article  PubMed  Google Scholar 

  29. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a huge review. Genet Med. 2005;7:463–78.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Urology, Central Hospital of Zhumadian City, Zhumadian City, Henan Province, 463000, China

    Hui Zhang, Xiuhua Wen & Xueren Lu

  2. Department of Nursing, Huanghuai University, Zhumadian City, Henan Province, 463000, China

    Hui Zhang

Authors
  1. Hui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiuhua Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xueren Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, H., Wen, X., Lu, X. et al. Association between NAD(P)H:quinone oxidoreductase 1 rs1800566 polymorphism and risk of bladder cancer. Tumor Biol. 34, 3377–3381 (2013). https://doi.org/10.1007/s13277-013-0909-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-0909-6

Keywords

Search

Navigation